Imac Holdings, INC 10-Q quarterly reports

IMAC Holdings reported a substantial increase in net loss and a worsening financial position, raising significant doubt about its ability to continue as a going concern.

IMAC Holdings reports a net loss of $2.1 million for Q2 2025, focusing on precision medicine in cancer treatment.

IMAC Holdings, Inc. reported a significant increase in net loss and cash burn for the first quarter of 2025, raising substantial doubt about its ability to continue as a going concern, despite a strategic pivot to precision cancer treatment.

IMAC Holdings, Inc. has filed an amended quarterly report for Q3 2024, restating previous financial statements due to preferred dividend accounting errors, revealing a significantly increased accumulated deficit and a substantial doubt about its ability to continue as a going concern.

IMAC Holdings, Inc. has filed an amended quarterly report for Q2 2024, restating prior financials due to preferred dividend accounting errors, while continuing its strategic shift to precision cancer medicine despite significant liquidity challenges and ongoing regulatory audits.

IMAC Holdings shifts focus to precision medicine in cancer treatment, reporting a net loss of $2.2 million for the third quarter of 2024, while discontinuing its previous clinic operations.

IMAC Holdings reports a net loss of $1.79 million for the six months ended June 30, 2024, as it transitions from regenerative medicine to precision cancer treatment.

IMAC Holdings reports its first quarter 2024 results, reflecting the discontinuation of its clinic operations and a strategic shift towards new business ventures.